Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2024, reflecting a pivotal year of strategic transformation and significant growth.
Alfasigma is excited to announce that new findings from the multicenter-multicountry GALOCEAN (ph4) and SELECTION (ph3) studies, focusing on patients with moderate to severe Ulcerative Colitis, will be presented at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO) 2025.
Alfasigma today unveiled Morpho, the new brand identity of its Contract Development and Manufacturing Organization (CDMO) Business Unit. This announcement was made at CPHI 2024, the most important event in the pharmaceutical sector, specifically for Contract Development and Contract Manufacturing, taking place in Milan from October 8 to 10.
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, IBD (Inflammatory Bowel Disease), gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis), Ulcerative Colitis, PBC (Primary Biliary Cholangitis)
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies are the main pathologies in which we offer solutions
We provide treatments to relieve symptoms and signs in patients affected by rheumatoid arthritis
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue
Alfasigma's business strategy is closely linked to the principles of sustainability. We support scientific popularization and play a proactive role in the areas of culture, art, and civil society. We recognize that a pharmaceutical company is also a cultural entity. The dignity of a person is not only about being healthy, but encompasses all aspects of life and the environment in which they live, reflecting an idea of the overall well-being of society.
You’re entering Alfasigma global website
I agree